These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 2125836)

  • 1. Encainide versus flecainide in the treatment of chronic resistant paroxysmal atrial tachyarrhythmias.
    Coumel P
    Cardiovasc Drugs Ther; 1990 Jun; 4 Suppl 3():579-84. PubMed ID: 2125836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Encainide versus flecainide for chronic atrial and junctional ectopic tachycardia.
    Kuck KH; Kunze KP; Schlüter M; Duckeck W
    Am J Cardiol; 1988 Dec; 62(19):37L-44L. PubMed ID: 3144166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of class IC antiarrhythmic agents for the treatment of coexisting supraventricular and ventricular tachycardia.
    Rinkenberger RL; Naccarelli GV; Berns E; Dougherty AH
    Am J Cardiol; 1988 Aug; 62(6):44D-55D. PubMed ID: 3136636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Flecainide and encainide.
    Furlanello F; Vergara G; Bettini R; Mosna G; Gramegna L; Disertori M
    Eur Heart J; 1987 Mar; 8 Suppl A():33-40. PubMed ID: 3107989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of encainide and flecainide on chronic ectopic atrial tachycardia.
    Kunze KP; Kuck KH; Schlüter M; Bleifeld W
    J Am Coll Cardiol; 1986 May; 7(5):1121-6. PubMed ID: 3082957
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of flecainide versus propafenone for the long-term management of symptomatic paroxysmal supraventricular tachyarrhythmias. Report from the Flecainide and Propafenone Italian Study (FAPIS) Group.
    Chimienti M; Cullen MT; Casadei G
    Eur Heart J; 1995 Dec; 16(12):1943-51. PubMed ID: 8682031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Encainide for resistant supraventricular tachycardia in children: follow-up report.
    Strasburger JF; Smith RT; Moak JP; Gothing C; Garson A
    Am J Cardiol; 1988 Dec; 62(19):50L-54L. PubMed ID: 3144168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and utility of flecainide acetate in the routine care of patients with supraventricular tachyarrhythmias: results of a multicenter trial. The Flecainide Supraventricular Tachycardia Study Group.
    Hopson JR; Buxton AE; Rinkenberger RL; Nademanee K; Heilman JM; Kienzle MG
    Am J Cardiol; 1996 Jan; 77(3):72A-82A. PubMed ID: 8607395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Encainide and flecainide: are they interchangeable?
    Saini V; Podrid PJ; Slater W; Lown B
    Am Heart J; 1989 Jun; 117(6):1253-8. PubMed ID: 2499169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New antiarrhythmic drugs: tocainide, mexiletine, flecainide, encainide, and amiodarone.
    Kreeger RW; Hammill SC
    Mayo Clin Proc; 1987 Nov; 62(11):1033-50. PubMed ID: 3118116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long term evaluation of flecainide acetate in supraventricular tachyarrhythmias.
    Mary-Rabine L; Telerman M
    Acta Cardiol; 1988; 43(1):37-48. PubMed ID: 3132008
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of tocainide, encainide, lorcainide and flecainide for supraventricular arrhythmias.
    Orning OM
    Eur Heart J; 1984 Sep; 5 Suppl B():81-6. PubMed ID: 6437821
    [No Abstract]   [Full Text] [Related]  

  • 13. Proarrhythmia, cardiac arrest and death in young patients receiving encainide and flecainide. The Pediatric Electrophysiology Group.
    Fish FA; Gillette PC; Benson DW
    J Am Coll Cardiol; 1991 Aug; 18(2):356-65. PubMed ID: 1906902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Encainide hydrochloride and flecainide acetate: two class 1c antiarrhythmic agents.
    Chase SL; Sloskey GE
    Clin Pharm; 1987 Nov; 6(11):839-50. PubMed ID: 3119276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Encainide for atrial fibrillation associated with Wolff-Parkinson-White syndrome.
    Rinkenberger RL; Naccarelli GV; Miles WM; Markel ML; Dougherty AH; Prystowsky EN; Heger JJ; Zipes DP
    Am J Cardiol; 1988 Dec; 62(19):26L-30L. PubMed ID: 3144164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of encainide, flecainide, imipramine and moricizine on ventricular arrhythmias during the year after acute myocardial infarction: the CAPS.
    Cardiac Arrhythmia Pilot Study (CAPS) Investigators
    Am J Cardiol; 1988 Mar; 61(8):501-9. PubMed ID: 2894169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Flecainide acetate for the treatment of atrial and ventricular arrhythmias.
    Apostolakis S; Oeff M; Tebbe U; Fabritz L; Breithardt G; Kirchhof P
    Expert Opin Pharmacother; 2013 Feb; 14(3):347-57. PubMed ID: 23294160
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inefficacy and proarrhythmic effects of flecainide and encainide for sustained ventricular tachycardia and ventricular fibrillation.
    Herre JM; Titus C; Oeff M; Eldar M; Franz MR; Griffin JC; Scheinman MM
    Ann Intern Med; 1990 Nov; 113(9):671-6. PubMed ID: 2121082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The clinical use of class IC antiarrhythmic drugs.
    Abi Samra F
    J La State Med Soc; 1989 May; 141(5):27-31. PubMed ID: 2499646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiarrhythmic agents for chronic ventricular arrhythmias.
    Nestico PF; Morganroth J
    Compr Ther; 1987 Apr; 13(4):26-35. PubMed ID: 3105950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.